Kali Inc (OTCMKTS: KALY) resurgence is gathering pace as a spike in trading volume continues to affirm renewed investor interest. The stock has once again started surging after coming under immense short selling pressure at the start of the year.
KALY Share Price Analysis
The announcement that the company is developing cannabis treatment for type 2 Diabetes is the latest catalyst fuelling the upside action. The company has also set sights on the $600 million cannabis beverage market with a new 25 mg CBD extract formulation, as it continues to strengthen its product line.
In addition, the company has inked a strategic partnership with Nouveau Life Pharmaceuticals Inc (OTCMKTS: NOUV) and Puration Inc (OTCMKTS: PURA) as part of an effort of coming up with cannabis pharmaceutical solutions. The trio has signed an agreement with Generex Biotechnology Corporation (OTCMKTS: GNBT) as part of the drive.
Investors have continued to push the stock up, in response to recent developments that affirm Kali-Extracts push for value in the multi-billion sector. After plunging to the $0.01 mark, the stock has once again started trending higher after powering through a tight trading range.
If recent price action activity is anything to go by, then Kali-Extracts could as well be on its way to 52-week highs of $0.03 mark. A rally followed by a close above the critical technical level should open the door for the stock to continue powering high on turning bullish.
Kali-Extracts is a cannabis-focused company engaged in the research and development of cannabis treatments. The company is currently working on cannabis treatments for various therapies as well as chronic pain. It also provides Pharmaceuticals with cannabis extracts and health wellness products.
Why Is Kali-Extracts Surging
Shares of Kali-Extracts are surging after a long period of consolidation on the company announcing plans to pursue opportunities in two multimillion industries. The company has embarked on a research and development drive as it seeks to come up with cannabis-infused treatments for addressing COPD and Type 2 Diabetes.
The new treatments will supplement the company’s pilot cannabis treatment for Chronic Obstructive Pulmonary Disease. Success on the development of cannabis treatments for addressing Type 2 Diabetes should expand the company’s footprint into the $64 billion diabetes market.
Even as the company continues to work on cannabis treatments, it is also in the process of strengthening its pipeline of products. Through a patented extraction process, the company has produced a 10mg formulation of Puration leading EVERx CBD sports product as it moves to make its debut in the $600 million Cannabis Beverage Market.
In addition to cannabis products development, Kaly also continues to generate revenue from its patented cannabis extraction processes.
Plans by Texas to remove hemp as a controlled substance is another development that continues to shore, Kali, extracts sentiments in the market. Such a move should enhance the company’s push for opportunities in the state, especially with its cannabis extraction lab.
“Just the type of market condition management is looking for to support the implantation of the previously announced cannabis extraction lab to be dedicated to the 100-acre hemp farm to be operated by partner Nouveau (NOUV) in Texas,” Kaly in a statement.
The company has already inked a strategic partnership with Nouveau as part of its push for opportunities in Texas. The two are to join forces on the development of proprietary hemp cultivar expected to enhance Kaley’s extract development.
Enhancing operations in Texas part of Kaley’s push for value in the cannabis sector. The company has been exploring ways of enhancing its sales channel in pursuit of additional revenue streams. Early in the year, the company secured a $100,000 wholesale order for its Hemp4mula CBD infused Gummies.
Kaly’s share price does not provide an accurate reflection of the company’s tremendous potential. The company has continued to show how focused it is about pursuing opportunities with a diversified product line.
Development of cannabis-infused treatments for addressing various unmet medical needs provides clear evidence of how focused the company is about securing its long-term prospects. The company is also expanding its retail chain as it looks to generate optimum returns from its product line as well as extraction lab.
Price gains in the market look set to be the order of the day, on investors taking note of the tremendous opportunity at stake as the company continues to refine its product line.
We will be updating our subscribers as soon as we know more. For the latest updates on KALY, sign up below!
Disclosure: We have no position in any of the stocks mentioned and have not been compensated for this article.